Association between circulating galectin‑3 levels and the immunological, inflammatory and nutritional parameters in patients with colorectal cancer

Shimura,Tatsuo; Shibata,Masahiko; Gonda,Kenji; Nakajima,Takahiro; Chida,Shun; Noda,Masaru; Suzuki,Satoshi; Nakamura,Izumi; Ohki,Shinji; Takenoshita,Seiichi

doi:10.3892/br.2016.696

Association between circulating galectin‑3 levels and the immunological, inflammatory and nutritional parameters in patients with colorectal cancer

Authors:
- Tatsuo Shimura
- Masahiko Shibata
- Kenji Gonda
- Takahiro Nakajima
- Shun Chida
- Masaru Noda
- Satoshi Suzuki
- Izumi Nakamura
- Shinji Ohki
- Seiichi Takenoshita
View Affiliations

Affiliations: Department of Cancer Biology and Electronics, Fukushima Medical University, Fukushima 960‑1295, Japan, Department of Gastrointestinal Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350‑1298, Japan, Department of Organ Regulatory Surgery, Fukushima Medical University, Fukushima 960‑1295, Japan
Published online on: May 30, 2016 https://doi.org/10.3892/br.2016.696
Pages: 203-207

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Galectin-3, a β-galactoside-binding lectin, exhibits pleiotropic biological functions and has a role as one of the immunological modulators. However, the associations between circulating galectin‑3 and immunological, inflammatory and nutritional parameters have not yet been fully elucidated. The serum concentration of galectin‑3 was examined in association with interleukin‑10 (IL‑10), IL‑12 and IL17 production, lymphocyte stimulation, neutrophil/lymphocyte ratio (NLR), white blood cell count (WBC), C‑reactive protein (CRP) and rapid turnover proteins, including retinol‑binding protein (RBP), prealbumin (PA) and transferrin (TF) in 50 patients with untreated colorectal cancers. Significant increases (P<0.05) were observed in the serum galectin‑3 levels in patients with untreated colorectal cancer (9.6±4.5 ng/ml) compared with the normal controls (3.2±1.6 ng/ml). Higher serum galectin‑3 concentrations were observed in patients with colon cancer (11.5±4.4 ng/ml) compared to in patients with rectal cancer (8.0±4.0 ng/ml) (P=0.005). The levels of circulating galectin‑3 inversely correlated with the production of IL‑10 (r=‑0.59, P<0.001), and IL‑12 (r=‑0.69, P<0.001). Galectin‑3 concentration also inversely correlated with the lymphocyte stimulation assay stimulation index (r=‑0.42, P=0.021). However, the level of serum galectin‑3 correlated with IL‑17 production (r=0.67, P<0.001). Serum galectin‑3 levels exhibited significant correlations with NLR (r=0.41, P=0.009), WBC (r=0.32, P=0.035), and CRP (r=0.63, P<0.001), and statistically significant inverse correlations with RBP (r=‑0.45, P=0.002), PA (r=‑0.46, P=0.001) and TF (r=‑0.72, P<0.001). Galectin‑3 may be one of the key factors in the regulation of immunological, inflammatory and nutritional conditions.

View Figures

View References

1	Akahani S, Nangia-Makker P, Inohara H, Kim HR and Raz A: Galectin-3: A novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 57:5272–5276. 1997.PubMed/NCBI
2	Danguy A, Camby I and Kiss R: Galectins and cancer. Biochim Biophys Acta. 1572:285–293. 2002. View Article : Google Scholar : PubMed/NCBI
3	Davidson PJ, Davis MJ, Patterson RJ, Ripoche MA, Poirier F and Wang JL: Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology. 12:329–337. 2002. View Article : Google Scholar : PubMed/NCBI
4	Lin HM, Pestell RG, Raz A and Kim HR: Galectin-3 enhances cyclin D(1) promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene. 21:8001–8010. 2002. View Article : Google Scholar : PubMed/NCBI
5	Dagher SF, Wang JL and Patterson RJ: Identification of galectin-3 as a factor in pre-mRNA splicing. Proc Natl Acad Sci USA. 92:1213–1217. 1995. View Article : Google Scholar : PubMed/NCBI
6	Newlaczyl AU and Yu LG: Galectin-3 - a jack-of-all-trades in cancer. Cancer Lett. 313:123–128. 2011. View Article : Google Scholar : PubMed/NCBI
7	de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, Bakker SJL and van der Harst P: The fibrosis marker galectin-3 and outcome in the general population. J Intern Med. 272:55–64. 2012. View Article : Google Scholar : PubMed/NCBI
8	Acosta-Rodríguez EV, Montes CL, Motrán CC, Zuniga EI, Liu FT, Rabinovich GA and Gruppi A: Galectin-3 mediates IL-4-induced survival and differentiation of B cells: Functional cross-talk and implications during Trypanosoma cruzi infection. J Immunol. 172:493–502. 2004. View Article : Google Scholar : PubMed/NCBI
9	Bernardes ES, Silva NM, Ruas LP, Mineo JR, Loyola AM, Hsu DK, Liu FT, Chammas R and Roque-Barreira MC: Toxoplasma gondii infection reveals a novel regulatory role for galectin-3 in the interface of innate and adaptive immunity. Am J Pathol. 168:1910–1920. 2006. View Article : Google Scholar : PubMed/NCBI
10	Ferraz LC, Bernardes ES, Oliveira AF, Ruas LP, Fermino ML, Soares SG, Loyola AM, Oliver C, Jamur MC, Hsu DK, et al: Lack of galectin-3 alters the balance of innate immune cytokines and confers resistance to Rhodococcus equi infection. Eur J Immunol. 38:2762–2775. 2008. View Article : Google Scholar : PubMed/NCBI
11	Ruas LP, Bernardes ES, Fermino ML, de Oliveira LL, Hsu DK, Liu FT, Chammas R and Roque-Barreira MC: Lack of galectin-3 drives response to Paracoccidioides brasiliensis toward a Th2-biased immunity. PLoS One. 4:e45192009. View Article : Google Scholar : PubMed/NCBI
12	Fukumori T, Takenaka Y, Yoshii T, Kim HR, Hogan V, Inohara H, Kagawa S and Raz A: CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res. 63:8302–8311. 2003.PubMed/NCBI
13	Silverman AM, Nakata R, Shimada H, Sposto R and DeClerck YA: A galectin-3-dependent pathway upregulates interleukin-6 in the microenvironment of human neuroblastoma. Cancer Res. 72:2228–2238. 2012. View Article : Google Scholar : PubMed/NCBI
14	Demotte N, Wieërs G, Van Der Smissen P, Moser M, Schmidt C, Thielemans K, Squifflet JL, Weynand B, Carrasco J, Lurquin C, et al: A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res. 70:7476–7488. 2010. View Article : Google Scholar : PubMed/NCBI
15	Breuilh L, Vanhoutte F, Fontaine J, van Stijn CM, Tillie-Leblond I, Capron M, Faveeuw C, Jouault T, van Die I, Gosset P, et al: Galectin-3 modulates immune and inflammatory responses during helminthic infection: Impact of galectin-3 deficiency on the functions of dendritic cells. Infect Immun. 75:5148–5157. 2007. View Article : Google Scholar : PubMed/NCBI
16	Wu SY, Yu JS, Liu FT, Miaw SC and Wu-Hsieh BA: Galectin-3 negatively regulates dendritic cell production of IL-23/IL-17-axis cytokines in infection by Histoplasma capsulatum. J Immunol. 190:3427–3437. 2013. View Article : Google Scholar : PubMed/NCBI
17	Chen HY, Fermin A, Vardhana S, Weng IC, Lo KF, Chang EY, Maverakis E, Yang RY, Hsu DK, Dustin ML and Liu FT: Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation at the immunological synapse. Proc Natl Acad Sci USA. 106:14496–14501. 2009. View Article : Google Scholar : PubMed/NCBI
18	Wang W, Guo H, Geng J, Zheng X, Wei H, Sun R and Tian Z: Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack. J Biol Chem. 289:33311–33319. 2014. View Article : Google Scholar : PubMed/NCBI
19	Tsuboi S, Sutoh M, Hatakeyama S, Hiraoka N, Habuchi T, Horikawa Y, Hashimoto Y, Yoneyama T, Mori K, Koie T, et al: A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans. EMBO J. 30:3173–3185. 2011. View Article : Google Scholar : PubMed/NCBI
20	Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E and Iacobelli S: Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res. 6:1389–1393. 2000.PubMed/NCBI
21	Iacovazzi PA, Notarnicola M, Caruso MG, Guerra V, Frisullo S, Altomare DF and Correale M: Serum levels of galectin-3 and its ligand 90k/mac-2bp in colorectal cancer patients. Immunopharmacol Immunotoxicol. 32:160–164. 2010. View Article : Google Scholar : PubMed/NCBI
22	Chen C, Duckworth CA, Zhao Q, Pritchard DM, Rhodes JM and Yu LG: Increased circulation of galectin-3 in cancer induces secretion of metastasis-promoting cytokines from blood vascular endothelium. Clin Cancer Res. 19:1693–1704. 2013. View Article : Google Scholar : PubMed/NCBI
23	Cheng D, Liang B and Li Y: Serum galectin-3 as a potential marker for gastric cancer. Med Sci Monit. 21:755–760. 2015. View Article : Google Scholar : PubMed/NCBI
24	Sakaki M, Oka N, Nakanishi R, Yamaguchi K, Fukumori T and Kanayama HO: Serum level of galectin-3 in human bladder cancer. J Med Invest. 55:127–132. 2008. View Article : Google Scholar : PubMed/NCBI
25	Saussez S, Lorfevre F, Lequeux T, Laurent G, Chantrain G, Vertongen F, Toubeau G, Decaestecker C and Kiss R: The determination of the levels of circulating galectin-1 and −3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol. 44:86–93. 2008. View Article : Google Scholar : PubMed/NCBI
26	Ulu M, Alacacioglu A, Yuksel E, Pamukk BO, Bozkaya G, Ari A, Yuksel A, Sop G and Alacacioglu I: Prognostic significance of serum galectin-3 levels in patients with hepatocellular cancer and chronic viral hepatitis. Saudi J Gastroenterol. 21:47–50. 2015. View Article : Google Scholar : PubMed/NCBI
27	Išić T, Savin S, Cvejić D, Marečko I, Tatić S, Havelka M and Paunović I: Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors. J Cancer Res Clin Oncol. 136:1805–1812. 2010. View Article : Google Scholar : PubMed/NCBI
28	Xie L, Ni WK, Chen XD, Xiao MB, Chen BY, He S, Lu CH, Li XY, Jiang F and Ni RZ: The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma. J Cancer Res Clin Oncol. 138:1035–1043. 2012. View Article : Google Scholar : PubMed/NCBI
29	Vereecken P, Zouaoui Boudjeltia K, Debray C, Awada A, Legssyer I, Sales F, Petein M, Vanhaeverbeek M, Ghanem G and Heenen M: High serum galectin-3 in advanced melanoma: Preliminary results. Clin Exp Dermatol. 31:105–109. 2006. View Article : Google Scholar : PubMed/NCBI
30	Bergström K and Lefvert AK: An automated turbidimetric immunoassay for plasma proteins. Scand J Clin Lab Invest. 40:637–640. 1980. View Article : Google Scholar : PubMed/NCBI
31	Kleine TO and Merten B: Rapid manual immunoturbidimetric and immunonephelometric assays of prealbumin, albumin, IgG, IgA and IgM in cerebrospinal fluid. J Clin Chem Clin Biochem. 18:245–254. 1980.PubMed/NCBI
32	Hittelet A, Legendre H, Nagy N, Bronckart Y, Pector JC, Salmon I, Yeaton P, Gabius HJ, Kiss R and Camby I: Upregulation of galectins-1 and −3 in human colon cancer and their role in regulating cell migration. Int J Cancer. 103:370–379. 2003. View Article : Google Scholar : PubMed/NCBI
33	Nakamura M, Inufusa H, Adachi T, Aga M, Kurimoto M, Nakatani Y, Wakano T, Nakajima A, Hida JI, Miyake M, et al: Involvement of galectin-3 expression in colorectal cancer progression and metastasis. Int J Oncol. 15:143–148. 1999.PubMed/NCBI
34	Yazawa T, Shibata M, Gonda K, Machida T, Suzuki S, Kenjo A, Nakamura I, Tsuchiya T, Koyama Y, Sakurai K, et al: Increased IL-17 production correlates with immunosuppression involving myeloid-derived suppressor cells and nutritional impairment in patients with various gastrointestinal cancers. Mol Clin Oncol. 1:675–679. 2013.PubMed/NCBI
35	Balkwill F and Mantovani A: Cancer and inflammation: Implications for pharmacology and therapeutics. Clin Pharmacol Ther. 87:401–406. 2010. View Article : Google Scholar : PubMed/NCBI
36	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
37	Inoue Y, Nezu R, Matsuda H, Takagi Y and Okada A: Rapid turnover proteins as a prognostic indicator in cancer patients. Surg Today. 25:498–506. 1995. View Article : Google Scholar : PubMed/NCBI
38	Vanlandingham S, Spiekerman AM and Newmark SR: Prealbumin: A parameter of visceral protein levels during albumin infusion. JPEN J Parenter Enteral Nutr. 6:230–231. 1982. View Article : Google Scholar : PubMed/NCBI
39	Delpeuch F, Cornu A and Chevalier P: The effect of iron-deficiency anaemia on two indices of nutritional status, prealbumin and transferrin. Br J Nutr. 43:375–379. 1980. View Article : Google Scholar : PubMed/NCBI